Bausch + Lomb's U.S. shares tracking record gain after Q4 beat

Bausch + Lomb

21/02/2024 17:56

** U.S.-listed shares of Canada's Bausch + Lomb Corp
 BLCO.N  up 10.6% at $16.14 on Weds, 6-week high, after eye care
firm's results top expectations
    ** BLCO on course for biggest one-day pct gain since co IPOd
in May 2022
    ** Co posts Q4 rev of $1.17 bln, above LSEG est of $1.11
bln, including 66% growth yr/yr (on constant currency basis) to
$307 mln at its pharma unit
    ** Rev at largest segment, vision care, rose 8% to $662 mln
    ** Q4 adj EPS of 24 cents beat consensus by 7 cents
    ** For 2024, co expects rev to grow 12%-14% to $4.6-$4.7 bln
    ** Meanwhile, Emergent BioSolutions  EBS.N  appoints former
BLCO CEO Joseph Papa as its new chief. EBS shares jumping >60%
on the session
    ** U.S.-listed BLCO shares now off 5.7% in 2024 and down
~13% over the past year

 (Lance Tupper is a Reuters market analyst. The views expressed
are his own)
 ((lance.tupper@thomsonreuters.com
lance.tupper@tr.com 1-646-279-6380))